Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...
Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...
Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...
Abstract: Patients with myelodysplastic syndromes (MDS) collectively have a high symptom burden and are also at risk of death from complications of cytopenias and acute myeloid leukemia. The goals of therapy for...
Maintenance therapy with norethandrolone may improve survival in elderly patients with acute myeloid leukemia (AML) without increasing toxicity, according to a study published in the Journal of Clinical Oncology....
Maintenance therapy with norethandrolone may improve survival in elderly patients with acute myeloid leukemia (AML) without increasing toxicity, according to a study published in the Journal of Clinical Oncology....
A group of Swedish researchers may have found a cost-efficient way of examining individual leukemia cells, which could transform treatment strategies and make care more personalized, according to a study published in...
A group of Swedish researchers may have found a cost-efficient way of examining individual leukemia cells, which could transform treatment strategies and make care more personalized, according to a study published in...
The significant out-of-pocket costs cancer patients face before Medicare Insurance drug benefits kick in may delay initiation of tyrosine-kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML), according...
The significant out-of-pocket costs cancer patients face before Medicare Insurance drug benefits kick in may delay initiation of tyrosine-kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML), according...
Monotherapy with which of the following drugs was found to improve response in patients with chronic lymphocytic leukemia after relapsing or becoming refractory to ibrutinib or...
Monotherapy with which of the following drugs was found to improve response in patients with chronic lymphocytic leukemia after relapsing or becoming refractory to ibrutinib or...
Patients with chronic lymphocytic leukemia (CLL) who are relapsed or refractory (R/R) to ibrutinib or idelalisib may benefit from venetoclax monotherapy, according to a study presented at the 2016 American Society of...
Patients with chronic lymphocytic leukemia (CLL) who are relapsed or refractory (R/R) to ibrutinib or idelalisib may benefit from venetoclax monotherapy, according to a study presented at the 2016 American Society of...